Single Ascending Dose of ASP3772 Study in Japanese Healthy Male and Female Adults, and Single Ascending Dose Study of ASP3772 in Comparison With PPSV23 in Japanese Elderly Male and Female Subjects

Healthy Volunteers Clinical Trial

Official title:

ASP3772 Phase 1 Study: Single Ascending Dose Study in Japanese Healthy Male and Female Adults, and PPSV23-controlled, Randomized, Single Ascending Dose Study in Japanese Elderly Male and Female Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04265911
• Other study ID #: 3772-CL-1011
• Status: Completed
• Phase: Phase 1
• Start date: February 19, 2020
• Est. completion date: November 7, 2020

Study information

• Verified date: April 2022
• Source: Affinivax, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly to Japanese healthy adults 20 to 49 years of age.

This study will also evaluate the safety and tolerability of 3 different dose levels of ASP3772 administered subcutaneously or intramuscularly, in comparison to the active comparator 23-valent pneumococcal polysaccharide vaccine (PPSV23) in Japanese elderly subjects 65 to 85 years of age.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 126
• Est. completion date: November 7, 2020
• Est. primary completion date: November 7, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 20 Years to 85 Years

Eligibility

Inclusion Criteria:

• Group 1: Subject is a healthy male or female between 20 and 49 years of age inclusive, at informed consent.

• Group 2: Subject is a male or female between 65 and 85 years of age inclusive, at informed consent who is healthy or has chronic controlled, stable disease with no change in disease severity, medical therapy and no hospitalization history in last 12 weeks from informed consent as determined by medical history, physical examination, and laboratory data.

• Female subject of non-childbearing potential; male subject not able to father children or who is able to father children and willing to use a highly effective method of contraception.

• Subject agrees not to participate in another interventional study while participating in the present study.

• Subject has a body mass index (BMI) range of 17.6 to 26.4 kg/m^2 inclusive in Group 1 and 15.4 to 28.6 kg/m^2 inclusive in Group 2, and body weight at least 50 kg for male and 40 kg for female at screening.

Exclusion Criteria:

• Subject has had previous vaccination with any licensed or investigational pneumococcal vaccine at any time.

• Subject has a history of microbiologically-proven invasive disease caused by Streptococcus pneumoniae.

• Subject has an immune disorder(s) (including autoimmune disease), clinical conditions requiring immunosuppressive drugs and/or a close relative who has congenital immunodeficiency.

• Group 1: Subject has any illness that requires medication or treatment.

• Group 2: Subject has any evidence of unstable or active clinically significant cardiovascular, gastrointestinal, endocrine, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease, e.g., uncontrolled hypertension, uncontrolled diabetes, heart failure, uncontrolled chronic obstructive pulmonary disease, end-stage renal disease, malignancy which is active and requires treatment.

• Subject has any clinically significant history of allergic conditions including drug allergies, asthma or anaphylactic reactions, but excluding untreated asymptomatic seasonal allergies just before study vaccine administration.

• Subject has a positive serology test for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (anti-HBc), hepatitis A virus antibodies (immunoglobulin M), hepatitis C virus antibodies (anti-HCV) or antigens/antibodies to human immunodeficiency virus (HIV) type 1 and/or type 2 at screening.

• Subject has/had febrile illness or symptomatic of viral, bacterial (including upper respiratory infection) or fungal (excluding skin infection) infection within 7 days prior to day 1.

Related Conditions & MeSH terms

• Healthy Volunteers

Intervention

Biological:
• ASP3772 (subcutaneous)
Subcutaneous injection
• ASP3772 (intramuscular)
Intramuscular injection
• PPSV23 (subcutaneous)
Subcutaneous injection
• PPSV23 (intramuscular)
Intramuscular injection

Locations

Country	Name	City	State
Japan	JP81001	Fukuoka

Sponsors (1)

Lead Sponsor	Collaborator
Affinivax, Inc.

Country where clinical trial is conducted

Japan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of participants with treatment emergent adverse events (TEAEs) including serious AEs (SAEs), medically attended adverse events (MAAEs), potentially immune mediated medical conditions (PIMMCs) and new onset chronic diseases (NOCDs)	An adverse event (AE) is any untoward medical occurrence in a subject administered an investigational product (IP), and which does not necessarily have to have a causal relationship with this treatment. TEAE is defined as an AE occurring after study immunization to the last visit (up to 30 days post-vaccination if the study is discontinued for an individual subject). An IP-related TEAE is defined as any TEAE with a causal relationship assessed as "yes" by the investigator or subinvestigator.	Up to Day 30
Primary	Percentage of participants with vital sign abnormalities and/or adverse events (AEs)	Percentage of participants with potentially clinically significant vital sign values.	Up to Day 30
Primary	Percentage of participants reporting solicited local adverse reactions	Local reactions include pain, tenderness, erythema/redness, swelling, and induration. The reaction will be graded with 4-range grade: 1 (mild) to 4 (potentially life-threatening).	Up to Day 7
Primary	Percentage of participants reporting solicited systemic adverse reactions	Systemic reactions include nausea, vomiting, diarrhea, headache, fever, fatigue and myalgia and arthralgia. Vital signs up to 7 days postvaccination are collected as systemic reactions. The reaction will be graded with 4-range grade: 1 (mild) to 4 (potentially life-threatening).	Up to Day 7
Primary	Percentage of participants with laboratory value abnormalities and/or adverse events (AEs)	Percentage of participants with potentially clinically significant laboratory values.	Up to Day 30
Primary	Percentage of participants with electrocardiogram (ECG) abnormalities and/or Adverse Events (AEs)	Percentage of participants with potentially clinically significant ECG values.	Up to Day 30
Primary	Percentage of participants with physical exam abnormalities and/or adverse events (AEs)	Percentage of participants with potentially clinically significant physical exam values.	Up to Day 30
Secondary	Geometric mean titer (GMT) for opsonophagocytic activity (OPA) for each serotype contained in ASP3772	OPA measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	GMT for OPA for each serotype contained in PPSV23	OPA measure will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30
Secondary	Ratio of the OPA GMT (each ASP3772 dose level/PPSV23)	OPA measure will be used to characterize the immunological response on Day 30 after administration of ASP3772 and PPSV23	On Day 30
Secondary	Geometric mean concentration (GMC) for pneumococcal serotype-specific anticapsular polysaccharide immunoglobulin G (PS IgG) for each serotype contained in ASP3772	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	GMC for pneumococcal serotype-specific anticapsular PS IgG for each serotype contained in PPSV23	PS IgG measure measure will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30
Secondary	Ratio of GMC for pneumococcal serotype-specific anticapsular PS IgG (each ASP3772 dose level/PPSV23)	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772 and PPSV23.	On Day 30
Secondary	Geometric mean fold rise (GMFR) in anticapsular PS IgG concentration on day 30 relative to pre-immunization contained in ASP3772	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	GMFR in anticapsular PS IgG concentration on day 30 relative to pre-immunization contained in PPSV23	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30
Secondary	GMFR in OPA titer on day 30 relative to pre-immunization contained in ASP3772	OPA titer will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	GMFR in OPA titer on day 30 relative to pre-immunization contained in PPSV23	OPA titer will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30
Secondary	Proportion of subjects with a = 4-fold increase relative to baseline in pneumococcal serotype-specific anticapsular PS IgG concentration for each serotype contained in ASP3772	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	Proportion of subjects with a = 4-fold increase relative to baseline in pneumococcal serotype-specific anticapsular PS IgG concentration for each serotype contained in PPSV23	PS IgG measure will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30
Secondary	Proportion of subjects with a = 4-fold increase relative to baseline in OPA titer for each serotype contained in ASP3772	OPA titer will be used to characterize the immunological response on Day 30 after administration of ASP3772.	On Day 30
Secondary	Proportion of subjects with a = 4-fold increase relative to baseline in OPA titer for each serotype contained in PPSV23	OPA titer will be used to characterize the immunological response on Day 30 after administration of PPSV23	On Day 30